30 May 2017 13:19
MYCELX Technologies Corporation
("MYCELX" or the "Company") (AIM: MYX)
30 May 2017
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). This inside information is now considered to be in the public domain.
Grant of Share Option to Chief Financial Officer
On 26 May 2017 Ms. Slayton was awarded the following options over the Company's common shares of US$0.025 each ("Common Shares") under the MYCELX Omnibus Performance Incentive Plan ("Plan"):
Name | Number of share options granted | Exercise price | Total number of share options held following this notification | Total number of share options as % of current issued share capital |
Kimberly Slayton | 30,000 | US$0.75* | 130,000 | 0.69% |
Ms. Slayton holds no Common Shares in the issued capital of the Company.
Grant of Share Option to Chief Business Development Officer
The Company further announces that Mark Mixon, Chief Business Development Officer, was granted an option on 26 May 2017 under the Plan over 35,000 Common Shares. The grant to Mr. Mixon was as follows:
Name | Number of share options granted | Exercise price | Total number of share options held following this notification | Total number of share options as % of current issued share capital |
Mark Mixon | 35,000 | US$0.75* | 300,204 | 1.60% |
In addition, following this transaction, Mr. Mixon continues to be interested in 10,000 Common Shares, representing 0.05 per cent of the present issued capital of the Company, which he holds as a custodian.
Grant of Share Option to Chief Executive Officer
The Company further announces that Connie Mixon, Chief Executive Officer, was granted an option on 26 May 2017 under the Plan over 40,000 Common Shares. The grant to Ms. Mixon was as follows:
Name | Number of share options granted | Exercise price | Total number of share options held following this notification | Total number of share options as % of current issued share capital |
Connie Mixon | 40,000 | US$0.75* | 203,017 | 1.08% |
Following this award, Connie Mixon, Chief Executive Officer and spouse of Mr. Mixon is interested in an aggregate (including the interests of Mr. Mixon) of 991,211 Common Shares, representing 5.28 per cent of the present issued capital of the Company, and in options over an aggregate (including the interests of Mr. Mixon) of 503,221 Common Shares, representing 2.68 per cent of the present issued capital of the Company.
The aggregate number of Common Shares held by Ms. Mixon also includes (a) 150,000 shares held by limited liability companies controlled by Ms. Mixon; and (b) 202,646 shares held by or on behalf of Ms. Mixon's children.
The above grants formed part of wider grants of 205,000 options to employees across the Company, on the same date, representing 1.09% of the current issued share capital.
The share options granted on 26 May 2017 will vest as to 50% on 31 December 2017 and 50% on 31 December 2018, and must be exercised prior to the tenth anniversary of the date of grant, subject to the restrictions on dealing under the Company's share dealing code.
Following the above grants, a total of 1,192,042 share options have been granted to directors and employees and are currently outstanding, representing 6.35% of the issued share capital of 18,770,117 Common Shares. *Based on the closing mid-market price of the Company's Common Shares at 26 May 2017, and the closing US/£ exchange rate at that date.
For further information please contact:
MYCELX Technologies Corporation Connie Mixon, CEO Kim Slayton, CFO |
Tel: +1 888 306 6843 |
Cantor Fitzgerald Europe - NOMAD and Broker Andrew Craig Richard Salmond |
Tel: +44 20 7894 7000 |
Celicourt Communications Mark Antelme Joanna Boon |
Tel: +44 20 7520 9266 |
The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation (No. 596/2014).
Notification of transactions of persons discharging managerial responsibility or connected persons
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||||||
a)
| Name
| Connie Mixon
| ||||||||||
2
| Reason for the notification
| |||||||||||
a)
| Position/status
| Director | ||||||||||
b)
| Initial notification /Amendment
| Initial notification | ||||||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||||||
a)
| Name
| Mycelx Technologies Corporation | ||||||||||
b)
| LEI
| 213800UJZINIK2VD1G48
| ||||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
Common shares of US$0.025
USU624551078
| ||||||||||
b)
| Nature of the transaction
| Grant of share option to Connie Mixon under the Mycelx Omnibus Performance Incentive Plan
| ||||||||||
c)
| Price(s) and volume(s)
|
| ||||||||||
d)
| Aggregated information
- Aggregated volume
- Price
|
n/a
n/a
| ||||||||||
e)
| Date of the transaction
| 2017/05/26 | ||||||||||
f)
| Place of the transaction
|
| ||||||||||
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||||||
a)
| Name
| Connie Mixon
| ||||||||||
2
| Reason for the notification
| |||||||||||
a)
| Position/status
| Director | ||||||||||
b)
| Initial notification /Amendment
| Initial notification | ||||||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||||||
a)
| Name
| Mycelx Technologies Corporation | ||||||||||
b)
| LEI
| 213800UJZINIK2VD1G48
| ||||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
Common shares of US$0.025
USU624551078
| ||||||||||
b)
| Nature of the transaction
| Grant of share option to spouse, Mark Mixon, under the Mycelx Omnibus Performance Incentive Plan
| ||||||||||
c)
| Price(s) and volume(s)
|
| ||||||||||
d)
| Aggregated information
- Aggregated volume
- Price
|
n/a
n/a
| ||||||||||
e)
| Date of the transaction
| 2017/05/26 | ||||||||||
f)
| Place of the transaction
|
| ||||||||||
Notes to Editors
MYCELX is a revolutionary oil-free water technology company solving the world's toughest oil removal problems in the oil and gas industry. The systems are based upon scientific breakthrough for a completely different approach to permanent oil removal. The Company created the patented MYCELX polymer using innovative molecular cohesion for removing oil from water far beyond what conventional systems have ever achieved. MYCELX systems remove oil to critically low levels in a much smaller physical footprint than conventional systems and in a virtually fail-safe process.
www.mycelx.com